October 17, 2019 / 6:30 AM / a month ago

AstraZeneca gets FDA priority review for experimental breast cancer drug

Oct 17 (Reuters) - Drugmaker AstraZeneca Plc said on Thursday its experimental breast cancer treatment will get a speedy review by the U.S. Food and Drug Administration, with a decision by the health regulator expected in the second quarter of next year.

The British company in March agreed to pay up to $6.9 billion to work with Japan’s Daiichi Sankyo Co Ltd on the treatment, trastuzumab deruxtecan or also known as DS-8201, in a direct challenge to the world’s biggest cancer drug maker Roche Holding AG.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below